ArticleBMC cancer2025

The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Wei Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.